SHENZHEN, CHINA, July 16, 2025 - (ACN Newswire via SeaPRwire.com) - On the morning of 15 July 2025, China Medical System Holdings Limited (“CMS” or the “Group”) rang the ceremonial bell to mark its official listing on the Singapore Exchange Main Board (Stock Abbreviation: CMS, Stock Code: 8A8).Nearly one hundred representatives from global professional institutions, shareholders, business partners and employees gathered to witness this strategic moment. Following its successful IPO on the Hong Kong Stock Exchange Main Board in September 2010 , CMS advances with formidable momentum onto the international capital platform, which will attract funds focusing on Asia-Pacific investments and local capital in Southeast Asia to optimize the shareholder structure. This listing also marks a significant milestone for the Group to deepen roots in emerging markets and advance industrial internationalization strategy.At the listing ceremony, Chairman, Chief Executive Officer and President of CMS, Mr. Lam Kong stated: “The secondary listing in Singapore represents a crucial step in implementing CMS’s Asia-Pacific strategy, demonstrating our commitment to extending China’s market advantages across the entire APAC region while strengthening our presence in Southeast Asia and the Middle East. This move not only facilitates CMS’s comprehensive and sustainable development in Asia-Pacific markets, but also enhances our international influence and competitiveness, enabling us to serve broader patient populations with high-quality and affordable medication options.” New CMS New AscentOver the 33-year journey, CMS has continuously challenged and surpassed itself through three strategic transformations to adapt to the external ecosystem: evolving from “China’s largest CSO” (1992-2010), to “transition from CSO to Pharma” (2010-2018), and since 2018, gradually establishing three core strategies of “Innovation-driven, Specialty Breakthroughs and Industrial Internationalization” to promote the upgrading and iteration of “New CMS”, accumulating momentum for takeoff.CMS has established a comprehensive pharmaceutical product lifecycle management system, covering every stage from target identification to clinical development, product registration and commercialization. The Group focuses on FIC (First-in-Class) and BIC (Best-in-Class) innovative products, and has meticulously built a pipeline of approximately 40 innovative products with differentiated advantages, among which 5 innovative drugs have been approved and successfully commercialized in China. With the impact of VBP (Volume-Based Procurement) mostly cleared, CMS has entered a new cycle of high-quality and sustainable development driven by exclusive and innovative drugs.In specialty fields, the Group focuses on cardio-cerebrovascular, gastroenterology, ophthalmology and skin health, continuously deepening product portfolios and expert networks. Notably, the Group’s skin health business “DERMAVON” has emerged as a leader in its sector and is proposed for an independent listing on the Main Board of the Hong Kong Stock Exchange.A Pioneer in Industrial Internationalization Synergized Development Across the Entire “R&D, Manufacturing and Commercialization” Value ChainSince 2022, CMS has initiated its “Industrial Internationalization” strategy by extending the Group’s advantages and resources from the Chinese market to emerging markets. Utilizing Singapore as the strategic pivot, the Group has established a localized cluster comprising CMS R&D, PharmaGend, and Rxilient, achieving synergized development across the entire pharmaceutical value chain from R&D to production and commercialization, driving deeper and broader market expansion across the Asia-Pacific region.Internationalization of the Commercialization System: Rxilient serves as a platform for drug introduction, R&D and commercialization, operated by a professional and experienced localized team. Headquartered in Singapore, its business has expanded to 14 countries and regions including Malaysia, Thailand, Vietnam, the Philippines, Indonesia, and the Middle East, helping partners from China, the US, and Europe bring innovative drugs to emerging markets while introducing more high-quality and affordable treatment options to local markets. As of now, Rxilient has cumulatively submitted marketing applications for nearly 20 drugs and medical devices across Southeast Asia, the Middle East, Hong Kong, Macao and Taiwan, covering therapeutic areas such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system.Internationalization of the Production System: PharmaGend, as an international CDMO platform based in Singapore, has a site spanning 30,000 square meters and is capable of manufacturing dosage forms such as tablets and capsules, with plans to expand production lines for injections, ointments, and nasal sprays. The factory has been certified by international authorities such as the FDA and the HSA, demonstrating its high-standard pharmaceutical manufacturing capabilities for global export .Structural factors including large population bases, healthcare insurance expansion and rising chronic disease burdens are transforming Southeast Asia, the Middle East and other emerging markets into new growth engines for the global pharmaceutical industry. Leveraging its integrated ecosystem, CMS is forming a novel model for Chinese pharmaceutical globalization - not only enabling incremental market conversion for its own products in emerging markets, but also providing global partners with a reliable one-stop solution, thereby generating additional growth momentum for the Group.Looking ahead, CMS will continue advancing its three core strategies to build the long-term value system of “New CMS”. By persistently enhancing accessibility to pharmaceutical innovation, CMS aims to benefit more patients, achieve sustainable healthy development, and deliver substantial value returns to investors.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2025 ACN Newswire via SeaPRwire.com.

WEST PALM BEACH, FL AND WINDSOR, ENGLAND, July 15, 2025 - (ACN Newswire via SeaPRwire.com) - U.S. Polo Assn., the official brand of the United States Polo Association (USPA), in partnership with Brand Machine Group (BMG), its licensing partner in the United Kingdom, proudly served once again as the Official Apparel and Team Sponsor for the 2025 Outsourcing Inc. Royal Charity Polo Cup. The prestigious event took place on July 11 at the renowned Windsor Great Park at Flemish Farms' Guards Polo Club.U.S. Polo Assn.(left to right) U.S. Polo Assn. Team Accepts Royal Charity Polo Cup Trophy: James Beim, HRH The Prince of Wales, J. Michael Prince (USPA Global), Boo Jalil (BMG), Aiyawatt Srivaddhanaprahba, and Amr ZedenIn its seventh consecutive year of sponsorship for the charitable event, U.S. Polo Assn. outfitted all participating polo players, umpires, and flaggers in custom-designed performance jerseys, with The Prince of Wales captaining the U.S. Polo Assn. Team. The annual event brought together elite polo players and distinguished guests for a day of sport and charitable giving.His Royal Highness The Prince of Wales competed in an exciting round-robin format match against Team Fortunis Bloodstock and Team Manta Marine Technologies - La Ilusión Polo Club. The high-profile charitable event featured other well-known polo players, including James Beim, Henry Porter, Jack Richardson, and Ivan Rubinich, to name a few. The match was filled with excellent gameplay from all participants, concluding with The Prince of Wales scoring the game-winning goal against Manta Marine Technologies. The Royal Charity Cup's Most Valuable Player was Emma McCrae from Team Fortunis Bloodstock, who had a great neck-shot goal during the day, alongside the Best Polo Pony, Chechu, played by HRH and owned by King Power Polo.In addition to performance gear, U.S. Polo Assn. provided a limited-edition 135th Anniversary commemorative gift to all event attendees, celebrating the brand's storied heritage dating back to 1890. The tailored gift set included a canvas tote bag, a 135th Anniversary cap, a pocket square, a lapel pin, the brand's newest issue of Field X Fashion magazine, as well as co-branded event caps developed exclusively for this occasion."It is an extraordinary honor to once again have The Prince of Wales lead the U.S. Polo Assn. Team in support of this meaningful charity event," said J. Michael Prince, President and CEO of USPA Global, the company which manages the global, multi-billion-dollar U.S. Polo Assn. brand. "We are proud to stand alongside our partner Brand Machine Group in raising critical funds and awareness through the sport of polo for very important causes that uplift communities across the United Kingdom."The annual high-profile philanthropic event raised more than £1.1 million for 10 important charities that are supported by The Prince and Princess of Wales. The 2025 event contribution takes the total raised from Royal Charity Polo Days played in the U.K. over the last 14 years to more than £14 million.Those charities include: Anna Freud Centre, British Red Cross, Child Bereavement UK, East Anglia's Children's Hospices, Family Action, Fields in Trust, Forward Trust, NHS Charities Together, Royal African Society, and We Are Farming Minds.In addition to U.S. Polo Assn.'s role as the Official Apparel and Team Sponsor, the 2025 Outsourcing Inc. Royal Charity Polo Cup was supported by a distinguished lineup of sponsors, including Lugano Diamonds, AUDI, and Whispering Angel. These prestigious brands joined forces to help elevate the experience for players and guests alike, while reinforcing the event's charitable mission through their shared commitment to excellence, philanthropy, and style."Participating in the 2025 Outsourcing Inc. Royal Charity Polo Cup again is one of the highlights of the British polo season for Brand Machine Group," said Boo Jalil, CEO of Brand Machine Group. "As the U.K. partner of U.S. Polo Assn., we are honored to help further connect the brand with the sport of polo and continue our shared mission of giving back through style and sport."Guards Polo Club is one of only four polo clubs in the United Kingdom that stage elite tournaments, such as the Royal Charity Polo Cup. Founded in 1955 as the Household Brigade Polo Club, with His Royal Highness Prince Philip, Duke of Edinburgh as President, the name was changed to the Guards Polo Club in 1969 and celebrates over six decades of premier polo.About U.S. Polo Assn. and USPA GlobalU.S. Polo Assn. is the official brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890 and based at the USPA National Polo Center in Wellington, Florida. This year, U.S. Polo Assn. celebrates 135 years of sports inspiration alongside the USPA. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,100 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. Historic deals with ESPN in the United States and Star Sports in India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, NBA, and MLB, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global and digital growth. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world. For more information, visit uspoloassnglobal.com and follow @uspoloassn.USPA Global is a subsidiary of the USPA and manages the global, multi-billion-dollar U.S. Polo Assn. brand. Through its subsidiary Global Polo Entertainment (GPE), USPA Global also manages Global Polo TV, which provides sports and lifestyle content. For more sports content, visit globalpolo.com.About Brand Machine Group (BMG)BMG is an international leader in fashion innovation, which has established itself as a vertical manufacturer and global licensing specialist with over four decades of industry experience. Partnering with recognized market leaders, BMG manages a seamless and collaborative process of designing, manufacturing, and delivering quality products while championing the DNA of a diverse portfolio of brands, spanning fashion, sports, outdoor, and homeware, including adult fashion, kidswear, and accessories.BMG's portfolio of brands includes U.S. Polo Assn. Penfield, New Balance Kids, Duchamp, Jack Wills, Flyers American Born, Lee Kids, Peckham Rye, Wrangler Kids, Juicy Couture. BMG reaffirms its commitment to upholding sustainable and ethical business practices by ensuring full transparency throughout its global supply chain, aligning with the ETI Base Code.Visit brandmachinegroup.com and follow @brandmachinegroup. For appointments, contact sales@brandmachinegroup.com.Photo Captions:1. (left to right) U.S. Polo Assn. Team Accepts Royal Charity Polo Cup Trophy: James Beim, HRH The Prince of Wales, J. Michael Prince (USPA Global), Boo Jalil (BMG), Aiyawatt Srivaddhanaprahba, and Amr Zeden2. HRH The Prince of Wales and Aiyawatt Srivaddhanaprahba Competing in the 2025 Outsourcing Inc. Royal Charity Polo Cup at Windsor Great Park at Flemish Farms' Guards Polo ClubPhoto Credit: Chris Jackson/Getty Images for Outsourcing Inc. Royal Charity Polo CupContact InformationShannon StilsonVP, Sports Marketing and Mediasstilson@uspagl.com+001.561.227.6994Gina DigregorioHead of Marketinggina.digregorio@brandmachinegroup.com+44 (0) 7741 635 984Stacey KovalskyVP, Global PR & Communicationsskovalsky@uspagl.com+001.561.790.8036SOURCE: U.S. Polo Assn.Related ImagesU.S. Polo Assn.HRH The Prince of Wales and Aiyawatt Srivaddhanaprahba Competing in the 2025 Outsourcing Inc. Royal Charity Polo Cup at Windsor Great Park at Flemish Farms’ Guards Polo Club Copyright 2025 ACN Newswire via SeaPRwire.com.

ROMEOVILLE, IL, July 15, 2025 - (ACN Newswire via SeaPRwire.com) - Formerra, a leader in performance materials distribution, today announced an agreement with GEON® Performance Solutions that designates Formerra as the preferred distributor of Foster®, LLC medical compounds in North America and South America.The agreement follows GEON's acquisition of Foster, LLC, and builds on Formerra's long-standing, global partnership with GEON for flexible and rigid PVC and filled polypropylene materials."This expanded partnership equips our customers with a broader set of proven medical-grade solutions while leveraging Formerra's technical guidance and robust supply-chain capabilities," said Kelly Wessner, Vice President, Key Accounts, Formerra. "Foster's brand strength and GEON's investment momentum create powerful growth potential for these materials and our customers."Foster, LLC brings more than 30 years of expertise in custom medical polymer compounding, offering highly engineered formulations. Ranging from radio-opaque and pre-colored to USP Class VI and ISO 10993-compliant grades, Foster materials serve critical applications such as medical device housings, drug-delivery and auto-injector components, surgical tools, and remote patient monitoring devices."It is a privilege to serve the high-growth healthcare and medical device industry as GEON embarks on this new journey with Foster and Formerra," said Arthur Adams, Chief Commercial Officer, GEON. "Our partnership with Formerra will expand our global footprint and enable us to distribute medical-grade engineered polymers to even more customers."With the addition of Foster, LLC compounds to its portfolio, Formerra further deepens its leading position in the healthcare space by delivering unmatched access to engineered medical polymers, deep regulatory expertise, and responsive logistics across the Americas.Key details--Formerra will distribute Foster®, LLC medical compounds in North and South America.--This agreement adds custom medical-grade compounds to Formerra's existing global access to GEON® PVC and filled PP materials.--Foster®, LLC material applications include medical device housings, drug-delivery and auto-injectors, surgical tools, remote patient monitoring components, and more.About FormerraFormerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways - driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.About GEONGEON® Performance Solutions is a global leader in the formulation, development and manufacture of performance polymer solutions. With a portfolio of highly adaptable vinyl and polyolefin polymer technologies as well as a full-service manufacturing business, GEON combines three powerful traditions into a single, customer-focused business. GEON Performance Solutions is a leading innovator in the development of performance material solutions for a broad range of markets including appliances, building & infrastructure, electronics, medical, transportation, power & communications and more. GEON Performance Solutions has approximately 1,200 global associates and 15 world-class manufacturing plants with headquarters in Westlake, Ohio. Please visit us at www.geon.com to learn more. GEON Performance Solutions is a portfolio company of SK Capital Partners.Media ContactJackie MorrisMarketing Communications Manager, Formerrajackie.morris@formerra.comSOURCE: Formerra Copyright 2025 ACN Newswire via SeaPRwire.com.

Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsinLead indication is non-CF bronchiectasis; ATL-105 targets disease drivers through a broad multimodal mechanism of actionVILNIUS, Lithuania, July 15, 2025 - (ACN Newswire via SeaPRwire.com) - AATec Medical GmbH ("AATec"), a biotech company developing a multi-product platform for the treatment of respiratory diseases, and Northway Biotech ("Northway Biotech" or "NBT"), a global Contract Development and Manufacturing Organization (CDMO), today announced a partnership for manufacturing process development and analytical development of AATec's lead product candidate, ATL-105, a proprietary, inhaled therapy based on recombinant alpha-1 antitrypsin (AAT) for non-cystic fibrosis bronchiectasis (NCFB).AATec Medical and Northway Biotech Announce PartnershipUnder the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop and scale the production process for ATL-105 using the Pichia pastoris expression system."With this partnership, we are establishing a robust and scalable production process for ATL- 105, laying the foundation for consistent quality for clinical development and commercial use," says Rüdiger Jankowsky, PhD, co-founder and CEO of AATec, and adds: "ATL-105 represents a new generation of inhaled biologics, combining anti-protease, anti-inflammatory, and antiinfective properties in one molecule. Delivered directly to the lungs, it enables fast, targeted action with minimal systemic exposure. We believe ATL-105 can redefine care in respiratory diseases with high medical need, such as non-CF bronchiectasis.""We are excited to support AATec in progressing towards clinical trials", shares Prof. Vladas Algirdas Bumelis, CEO and Chairman of Northway Biotech. "AATec is advancing a promising therapeutic solution addressing significant unmet medical needs, supported by a highly capable and dedicated team. With our decades of expertise in microbial systems, we are well-positioned to scale this program efficiently and deliver quality at every step.""We have recognized the opportunity to support a program that could meaningfully advance care for patients with respiratory diseases," adds André Markmann, PhD, VP of Business Development at Northway Biotech. "Inhaled protein therapies are gaining significant traction, and ATL-105 stands out as one of the most promising approaches in this area."AATec develops ATL-105 to treat NCFB, a chronic inflammatory respiratory condition which affects millions of people worldwide. This debilitating disease is marked by dilated bronchi, persistent inflammation, frequent airway infections and impaired mucus clearance. In addition to NCFB, ATL-105 has therapeutic potential for a broader range of inflammatory and infectious respiratory diseases, such as COPD, ARDS and other indications, reflecting the versatility of its anti-inflammatory, immunomodulatory, and anti-infective properties.About AATec MedicalAG AATec Medical GmbH is a biotechnology company developing a product platform based on a novel recombinant version of alpha-1 antitrypsin (AAT) for the treatment of respiratory inflammatory diseases, airway infections and rare diseases. The company has successfully demonstrated proof-of-principle in several indications and is currently preparing for a proof-ofconcept clinical trial with the first product candidate ATL-105 for inhaled application in non-CF bronchiectasis. AATec was founded by a seasoned interdisciplinary team with long-standing experience in clinical research, biopharmaceutical development and product industrialization. For further information, please visit https://www.aatec-medical.com/ and follow AATec on LinkedIn.About Northway BiotechNorthway Biotech is a leading CDMO specializing in protein-based biologics and gene therapies, offering comprehensive, end-to-end biopharmaceutical development and manufacturing services. With deep expertise in cell line development, process optimization, and cGMP manufacturing, Northway Biotech supports programs from early-stage development through to commercial production. Founded in 2004, the privately held company operates state-of-the-art facilities in Lithuania and the United States, delivering high-quality, compliant solutions tailored to each client's unique needs. For further information, please visit https://www.northwaybiotech.com.Northway Biotech Contact:Prof. Vladas Algirdas BumelisCEO and Chairman of the Boardvladas.bumelis@northwaybiotech.comAATec Medical Contact:Dr. Rüdiger Jankowsky, CEOinfo@aatec-medical.comMedia Contact:MC ServicesKatja Arnold, Julia von Hummelaatec-medical@mc-services.euPhone: +49 (0)89 2102280SOURCE: Northway Biotech Copyright 2025 ACN Newswire via SeaPRwire.com.

Forum will take place on Tuesday 22 July 2025, from 1:30 PM onwards, at Suntec Singapore Convention & Exhibition Centre, Level 3Guest-of-Honour, Ms Low Yen Ling, Senior Minister of State, Ministry of Culture, Community and Youth & Ministry of Trade and Industry will deliver keynote addressThis year’s theme is Industry, Business, and Regulatory Perspectives on Climate Change Mitigation and AdaptationSINGAPORE, July 15, 2025 - (ACN Newswire via SeaPRwire.com) - ONERHT Foundation has announced the 8th edition of the Greening ASEAN: Initiatives and Leadership (“GAIL”) Forum, which will take place on Tuesday 22 July 2025 from 1:30 PM at the Suntec Singapore Convention & Exhibition Centre, Level 3 (Rooms 334 to 336). The upcoming forum will gather business leaders, policymakers, and sustainability experts from across the region to examine industry, business, and regulatory perspectives on climate mitigation and adaptation in ASEAN. The forum will be graced by Ms Low Yen Ling, Senior Minister of State, Ministry of Culture, Community and Youth & Ministry of Trade and Industry, as the Guest-of-Honour, who will deliver the keynote address.This year’s theme explores Industry, Business, and Regulatory Perspectives on Climate Change Mitigation and Adaptation. Participants can look forward to an engaging half-day programme featuring keynotes and discussions focused on navigating the challenges and opportunities presented by sustainability imperatives, climate regulations, and evolving business models. The forum provides a unique opportunity to understand emerging trends, collaborate across sectors, and build capacity for lasting environmental impact.Ms Ch’ng Li-Ling, Director of RHT GRACE Institute, said, “Sustainability has moved to the centre of business strategy. It now underpins long-term value creation and corporate resilience.” Ms Kaylee Kwok, Chairman of ONERHT Foundation, said, “As ONERHT Foundation marks its 10th anniversary this year, our annual GAIL Forum continues to drive these critical conversations, equipping business and government leaders with the tools to lead effectively in a rapidly evolving landscape.”Key highlights of this year’s forum will be a fireside chat entitled “The Future of Green Leadership in ASEAN – How Businesses and Professional Services Can Drive Impact”, “Presentation on Navigating ASEAN’s Green Transition: Legal and Policy Pathways”, and “Developing and Investing in Carbon Markets in Asia: Business and Regulatory Perspectives”, featuring distinguished leaders and speakers in sustainability and governance. The sessions will spotlight practical and visionary approaches needed to catalyse meaningful climate action across the region.Launched by ONERHT Foundation in 2018, the GAIL Forum has grown into an annual platform for advancing climate resilience and sustainable business practices across ASEAN. By convening industry leaders and policymakers, the forum equips businesses with the knowledge, strategies, and confidence to embed sustainability at the core of their operations.For more information and to register for the ONERHT Foundation GAIL Forum 2025, please visit: https://www.gail2025.com/ ONERHT Foundation LtdA Singapore registered charity and grant-making philanthropic organisation, ONERHT Foundation Ltd (“Foundation”) enables RHTLaw Asia LLP and the RHT Group of Companies (collectively, “ONERHT”) to do right and do good through various charitable endeavours. Set up by ONERHT in 2015, the Foundation was registered as a Singapore charity by the Commissioner of Charities and a grant-making philanthropic organisation by the Inland Revenue Authority of Singapore on 16 September 2016 and 28 November 2016 respectively. The Foundation seeks to establish, inspire and encourage the right philanthropic culture among the corporate and legal fraternity of giving back to the community in a focused, hands-on and meaningful manner. Since its inception, the Foundation has raised more than S$5.5 million to support more than 35 beneficiaries involved in education, the environment protection and sustainability, disadvantaged groups as well as the arts and sports. For more information, please visit www.onerht.foundationRHT GRACE Institute LtdRHT GRACE Institute (“RGI”) is a social enterprise launched by ONERHT Foundation Ltd in 2020. RGI seeks to establish a culture and creed of raising consciousness, encouraging ethical leadership, and growing a community of values-aligned mindfully ethical leaders, professionals, and businesses. The mission of RGI is anchored on the core principles based on Governance, Risk, AML, Compliance & ESG (G.R.A.C.E.) within an organisation’s business model, infusing these into its culture, and influencing and impacting leaders, professionals and individuals by setting a precedent and standard for what is expected in decision making and behaviour. The vision of RGI elevates an organization from good to great, embedding its principles in members’ business models, organizational strategy and decision-making processes and influencing them to become custodians and champions of G.R.A.C.E. principles. RGI runs the podcast “EthBeats: Lessons in G.R.A.C.E.ful Living”.For media enquiries, please contact: Melody Ong / melody@waterbrooks.com.sg / +65 8901 9780General enquiries query@waterbrooks.com.sg Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, July 15, 2025 - (ACN Newswire via SeaPRwire.com) - The Payment Cards Group Limited (“PCG”), a cloud-native payment processor and acquirer, is reshaping the digital payment landscape through disruptive innovation, powering Hong Kong’s digital transformation and smart city development. In June 2025, PCG’s digital payment acceptance business, Yedpay, collaborated with Big Boss Taxi, a taxi fleet operator to introduce a wide range of digital payment options including Octopus, revolutionizing taxi payment experience and ushering the transportation sector into a new digital era. In addition, Yedpay’s solutions empowered Hong Kong’s first floating bar, STAY BAR, to break away from traditional business models, significantly enhancing customer experience and driving revenue growth. In June, PCG and its member, BBMSL, celebrated their relocation to a new office, marking a new chapter in the Group’s development. With innovation at its core, PCG is transforming Hong Kong’s payment ecosystem, guiding industries to embrace the digital era and paving the way for a brighter future as a smart city.Yedpay collaborates with Big Boss Taxi to promote cashless taxi paymentsAs an acquirer with principal memberships in all major card schemes, Yedpay delivers tailored digital payment solutions for diverse industries. Octopus Holdings Limited recently announced a partnership with Big Boss Taxi to launch a comprehensive taxi ecosystem solution that integrates ride-hailing, digital payments, and more. PCG, in collaboration with Big Boss Taxi, integrated POS terminals with taxi meters to support multiple payment methods, including Octopus, credit cards, and e-wallets, enabling seamless and efficient taxi payments for passengers. Big Boss Taxi will launch full services in July, offering passengers a frictionless ride experience powered by cashless payments. Digital payments fuel revenue growth for local barBeyond its collaboration with local taxi fleet operator, Yedpay assisted STAY BAR, Hong Kong’s first floating bar, seize the trend of digital consumption, thereby attracting more tourists and local customers and contributing to continuous revenue growth. By supporting over 21 payment methods, including Alipay, WeChat Pay, and credit cards, Yedpay enabled STAY BAR to deliver seamless and convenient checkout experience for a diverse clientele. With transparent pricing and prompt customer support, Yedpay further enhanced STAY BAR’s operational efficiency. Committed to advancing a cashless society, Yedpay provides flexible and innovative payment solutions that support sectors such as transportation, food and beverage, and retail, enhancing operational efficiency and customer experiences, and stimulating local spending amid sluggish consumption. Video link: https://www.facebook.com/share/r/19Lj6ZYPFp/New office: a milestone for innovation and growthIn June, PCG and its member BBMSL hosted a new office warming party, celebrating the successful relocation and fostering stronger connections among staff members. The new office not only enhances the working environment but also injects vitality into the Group’s innovation and collaboration efforts. PCG extends its gratitude for the support from all sectors and remains committed to delivering innovative payment solutions to more merchants, thereby advancing Hong Kong’s development as a smart city.PCG New Address:Suites 601-2 & 10-14, 6/F, North Tower, World Finance Centre, 19 Canton Road, Harbour City, Tsim Sha Tsui, Kowloon, Hong KongAbout Payment Cards Group (“PCG”)The Payment Cards Group Limited (“PCG”) is an innovative and leading payment technology company with operations in Singapore, Hong Kong and the Asia-Pacific region. Established in 2016, PCG has become an acquirer with principal memberships in all major card schemes and e-wallet networks. Yedpay, a member of PCG, has firmly established itself as a digital payment acceptance business in Hong Kong. Meanwhile, A3A, another member of PCG, has developed a cloud-native payment processing platform that operates through RESTful APIs, significantly reducing costs and streamlining complex processes while providing users with real-time transaction data and insights. As an acquiring processor, PCG serves as the backbone infrastructure of the entire payment industry by its Asia’s 1st cloud-based processing and settlement platform. Rooted in Hong Kong with a global vison, PCG seeks to empower merchants with cutting-edge payment technology solutions and drive high-quality development in the global payment ecosystem. For more information, please visit PCG’s website: https://www.yedpay.com/en/For media enquiries, please contact:AJA (IR and Communications)Avy YuTel: (852) 9500 4443Email: avy.yu@ajacapital.com.hk/info@ajacapital.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

Brisbane, Queensland, Australia - (ACN Newswire via SeaPRwire.com - July 14, 2025) - Graphene Manufacturing Group Limited (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce that the patent for the Company's Graphene Aluminium Ion Battery has been granted in Australia and GMG is progressing its patenting process in various other countries. The University of Queensland (UQ) holds the patent and GMG has a worldwide exclusive commercialisation license. Figure 1 shows a typical Graphene Aluminium Ion Battery Pouch Cell Prototype which GMG is currently co-developing with Rio Tinto and UQ.Figure 1: Typical G+AI Battery Pouch Cell PrototypeTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/258713_gmg_figure1_550.jpgFurthermore, GMG has signed a Collaborative Research Agreement with UQ - Australian Institute for Bioengineering and Nanotechnology (AIBN) to continue its collaboration on the Graphene Aluminium Ion Battery. UQ is also a recipient of AU$880,000 of Australian Government grant funding to further develop the Graphene Aluminium Ion Battery.Figure 2To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/258713_gmg_figure2_550.jpgGMG and UQ started working on an Australian Research Council (ARC) Linkage Project in 2021 to co-develop the Graphene Aluminium Ion Battery and this will now continue under this new Collaborative Research Agreement.The Agreement sets out, among other things, the way in which pre-agreed GMG and UQ personnel can work at each other party's premises and the intellectual property rights and obligations for each party. It also provides that GMG has the exclusive first right to negotiate an exclusive license to use any of the work UQ develops under this Agreement.UQ's Professor Alan Rowan, AIBN Executive Director, commented "We look forward to continuing our strong research and development relationship with the world leading clean technology company GMG and deepening our knowledge on the graphene aluminium ion battery technology."GMG's Managing Director and CEO, Craig Nicol, commented: "GMG is very pleased to continue working with the world leading UQ AIBN team and collaborating with them to co-develop our next generation Graphene Aluminium Ion Battery."As previously announced on March 3, 2025, GMG has entered into a service contract with the Battery Innovation Center (BIC) of Indiana in the United States of America to support the next phase of development of the Graphene Aluminium Ion Battery. As a result, GMG is no longer focused on a project to construct an Automated Battery Pilot Plant at its Richlands Australia headquarters at this time. GMG and the State of Queensland have mutually agreed to an early termination of the Queensland Critical Minerals and Battery Technology Fund Agreement between the parties.About UQ & AIBN:Ranked in the world's top 50, The University of Queensland is one of Australia's leading research and teaching institutions. As part of UQ, the Australian Institute for Bioengineering and Nanotechnology (AIBN) is a leading research institute which tackles global challenges in health, energy, and the bioeconomy. It works on projects like mRNA manufacturing, diagnostics, and sustainable solutions. AIBN collaborates with industry and government and are known for their work in advanced biomanufacturing, nanoengineered materials, and precision nanomedicine.About GMG:GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking Statements This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, the development of the Graphene Aluminium Ion Battery Pouch Cell Prototype, the future collaboration between GMG and UQ-AIBN, the further development of the Graphene Aluminium Ion Battery and GMG's intentions for the Automated Battery Pilot Plant at its Richlands Australia headquarters, the further development of the Graphene Aluminium Ion Battery with the BIC of Indiana.Such forward-looking statements are based on a number of assumptions of management, including amongst others, the successful repeatability and scalability of the Graphene Aluminium Ion Battery cells, the successful electrochemistry optimisation of the Graphene Aluminium Ion Battery, the energy density of the Graphene Aluminium Ion Battery reaches the required performance level for customer adoption, successful customer adoption of the Graphene Aluminium Ion Battery, successful pilot plant and production scale up of the Graphene Aluminium Ion Battery, the Graphene Aluminium Ion Battery is competitive against other technologies with respect to cost, performance, safety and other parameters, the Graphene Aluminium Ion Battery safety is validated by external testing and customers, the Company is able to get the required approvals for production and sale of the Graphene Aluminium Ion Battery, the Graphene Aluminium Ion Battery expected costs are within acceptable range to produce and sell profitably, the Company can fund the capital required to produce the Graphene Aluminium Ion Battery at scale and global market trends continue to incentivise industries to adopt batteries for use. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: technical risks for the repeatability, scalability, electrochemistry optimisation and performance uncertainty, commercialisation risks for the pilot plant success, customer testing, market adoption and industry inertia, safety and regulatory risks for the safety validation and regulatory approvals, supply chain risks for the sourcing of raw materials and local manufacturing challenges, financial and market risks for the capital requirements and market volatility, risks relating to the extent and duration of the conflict in Eastern Europe and its impact on global markets, the volatility of global capital markets, political instability, attract and retain skilled personnel, unexpected development and production challenges, unanticipated costs and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated October 3, 2024 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/258713 Copyright 2025 ACN Newswire via SeaPRwire.com.

SINGAPORE, July 15, 2025 - (ACN Newswire via SeaPRwire.com) - Mooreast Holdings Ltd. (“Mooreast” or the “Group”) said today that it has partnered with Norway-based GeoProvider AS (“GeoProvider”) to strengthen capabilities in offshore data analysis and enhance its value proposition to the floating offshore renewable energy market.Through their Framework Agreement, Mooreast will tap into GeoProvider’s extensive geotechnical and geophysical database to accelerate data analysis and support larger, more complicated projects. Both parties will also collaborate on offshore wind projects as the floating renewable market transitions towards the commercialisation phase.SGX Catalist-listed Mooreast, a total mooring solutions specialist, has been offering geotechnical and geophysical studies, such as soil data analysis to determine project feasibility and engineering design for mooring configurations. The Group is also Asia’s only ultra-high power anchor manufacturer.Headquartered in Stavanger, Norway, GeoProvider provides geophysical data and geotechnical services for global clients involved in offshore wind, energy exploration and carbon capture and storage. Its team of world-class specialists and cutting-edge technology offers consultancy, advisory, and engineering for subsurface projects.Mr Eirik Ellingsen, CEO of Mooreast, said, “The agreement with GeoProvider reflects our strategy to build strong partnerships that add value to our clients and increase our capability to take on larger and more complex projects. GeoProvider’s strong track record complements our core competencies as a mooring specialist, allowing us to better meet the demands of the global offshore market.”In line with these efforts, Mooreast also signed a Memorandum of Understanding (“MoU”) with Korea Ocean Engineering & Consultants Co., Ltd. (“KOCECO”) to promote joint business and technology collaboration in offshore mooring and seabed anchoring solutions.KOCECO, recognised by South Korea’s Ministry of Trade, Industry and Energy, brings extensive experience in submarine cable laying and underwater engineering services. The MoU lays the groundwork for future cooperation in the rapidly developing floating offshore wind market in North Asia, where Mooreast seeks to play a pivotal role in addressing local supply chain gaps in mooring systems.“The two agreements will significantly strengthen Mooreast’s global position and our commitment to our transformation to serve the renewable energy sector. Through these partnerships, we are now better equipped to deliver a comprehensive solution for the offshore sector,” added Mr Ellingsen.This press release has been reviewed by the Company’s sponsor, UOB Kay Hian Private Limited (the “Sponsor”). This press release has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “SGX-ST”) and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.The contact person for the Sponsor is Mr Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10- 01 UE Square, Singapore 239920, telephone (65) 6590 6881.Issued for and on behalf of Mooreast Holdings Ltd. by WeR1 Consultants Pte Ltd.About Mooreast Holdings Ltd.Mooreast is a total mooring solutions specialist, serving mainly the offshore renewable energy, offshore oil & gas (“O&G”) and marine industries, with operations primarily in Singapore, the Netherlands through its wholly-owned subsidiary in Rotterdam Mooreast Europe, and offices based in Scotland, Taiwan and Malaysia.Mooreast’s solutions include the design, engineering, fabrication, supply and logistics, installation and commissioning of mooring systems. Mooreast is applying its experience and expertise in mooring solutions to floating renewable energy projects, in particular floating offshore wind farms. It has successfully participated in developmental and prototype projects for floating offshore wind turbines in Japan and Europe.For more information, please visit https://mooreast.com/Media & Investor Contact InformationWeR1 Consultants Pte Ltd1 Raffles Place #02-01One Raffles Place Mall Suite 411Singapore 048616Isaac Tang, mooreast@wer1.net (M: +65 9748 0688) Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, July 15, 2025 - (ACN Newswire via SeaPRwire.com) - July 14, 2025, Bluemount Holdings Limited (Nadsaq: BMHL) (“Bluemount” or the “Company”), a Hong Kong-based consulting and advisory and financial services provider, as well as trader of commodities such as luxury timepieces, today announced the closing of its underwritten initial public offering (the “Offering”) of 1,375,000 Class B Ordinary Shares at a public offering price of $4.00 per share, for aggregate gross proceeds of approximately $5.5 million, prior to deducting underwriting discounts and other offering expenses. The Offering closed on July 14, 2025 and the Company’s Class B Ordinary Shares began trading on Nadsaq on July 11, 2025, under the symbol “BMHL.”In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 206,250 Class B Ordinary Shares at the public offering price per share to cover over-allotments, if any.Dominari Securities LLC acted as the representative of the underwriters, and Pacific Century Securities, LLC and Revere Securities LLC acted as co-underwriters to the Offering. Loeb & Loeb LLP acted as legal counsel to the Company and VCL Law LLP acted as legal counsel to the underwriters for the Offering.The Offering is being conducted pursuant to the Company’s registration statement on Form F-1, as amended (File No. 333-285843), relating to the shares being sold in the Offering initially filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 17, 2025, and was declared effective by the SEC on June 30, 2025. The Offering was made only by means of a prospectus. A final prospectus relating to the Offering has been filed with the SEC on July 11, 2025, and is available on the SEC’s website at www.sec.gov. Copies of the final prospectus related to the Offering may be obtained from Dominari Securities LLC, 725 5th Ave, 23rd Floor, New York, NY 10022, Telephone: (212) 393-4500; Email: investmentbanking@dominarisecurities.com. Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.Forward-Looking StatementsThis press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the intended use of the proceeds. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “anticipate”, “estimate”, “expect”, “project”, “plan”, “intend”, “believe”, “may”, “will”, “should”, “can have”, “likely” and other words and terms of similar meaning. Forward-looking statements represent the Company’s current expectations regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.About Bluemount Holdings Limited Bluemount Holdings Limited, through its operating subsidiaries, is a Hong Kong-based consulting and advisory and financial services provider, as well as trader of commodities such as luxury timepieces. For its consulting and advisory services business segment, it provides comprehensive consulting and advisory services on business development strategies to its diverse clientele. Its financial services segment focuses on the provision of (i) underwriting and placing services; (ii) securities dealing and brokerage services; and (iii) asset management services. It also operates a subsidiary that is dedicated to the trading of luxury branded timepieces, where it sources, buys, and sells prestigious timepieces. For more information, visit http://www.bluemount.com and http://www.bluemount-commodities.com.Investor Relations Contact:Chan Wan Shan Sandra, CEOBluemount Holdings LimitedRoom 1007, Capital Centre151 Gloucester Road, Wan Chai,Hong Kong(+852) 2137 2688Email: investors@bluemount.com Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, July 15, 2025 - (ACN Newswire via SeaPRwire.com) - Galaxy Payroll Group Limited (Nasdaq: GLXG) ("Galaxy" or the "Company"), a leading global payroll provider, today announced the execution of definitive agreements with select accredited investors for a private investment in public equity ("PIPE") transaction.On July 11, 2025, the Company entered into a Securities Purchase Agreement ("SPA") under which it will issue and sell 15,000,000 Class A ordinary shares, each with a par value of US$0.000625, at a price of US$0.33 per share. Concurrently, the Company executed a Registration Rights Agreement ("RRA") granting investors customary registration rights for these shares. The transaction will generate gross proceeds of approximately US$4.95 million, subject to satisfaction of customary closing conditions stipulated in the SPA.Mr. Wai Hong Lao, Chairman and Chief Executive Officer of Galaxy Payroll Group, stated: "This PIPE financing represents a strategic step in strengthening our capital structure to support Galaxy's global expansion initiatives. We remain focused on advancing our technology-driven payroll solutions while maintaining rigorous compliance with all regulatory obligations to our shareholders and partners."About Galaxy Payroll Group LimitedGalaxy Payroll Group Limited is a leading payroll outsourcing service provider based in Hong Kong. The company specializes in delivering HR and payroll solutions to multinational companies across various industries. With a focus on innovation and client satisfaction, GLXG operates in Hong Kong, Taiwan, Macau, and the PRC, offering payroll outsourcing, employment services, and consultancy to businesses of all sizes.For more information, please visit Galaxy Payroll Group's website: www.galaxyapac.com.Forward-Looking StatementsMatters discussed in this press release may constitute forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The words "believe," "anticipate," "intends," "estimate," "potential," "may," "should," "expect" "pending" and similar expressions identify forward-looking statements. The forward-looking statements in this press release are based upon various assumptions. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations.For enquiry, please contact Intelligent Joy Limited:Karen DengPhone: (852) 3594 6407Email: pr-team@intelligentjoy.com Copyright 2025 ACN Newswire via SeaPRwire.com.